{"name":"Atara Biotherapeutics","slug":"atara-biotherapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNnE3dklXWEtQUzZLWlBGMkRtQk9Fb2FZeHlLUlg2TllxZ3ZfblMxMjU0WHRFOEJfVFl5Y29aeTNZb3c5c1VJZzBRMXNSU1RGb2dlRFZLb3hWQWtfa1d4T3E5cWh2UGU4WlN0RWJOSDluMHZ0MnVKcWVIb2FFX05zNE05cUtsa3l5ZHlOMXRFTFdWTGpRckluUEtQWQ?oc=5","date":"2026-03-03","type":"regulatory","source":"BioPharma Dive","summary":"Pierre Fabre seeks to revive US approval chances for spurned cell therapy - BioPharma Dive","headline":"Pierre Fabre seeks to revive US approval chances for spurned cell therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPcDRYVTdpUFdoYl9hT0xJYUZUN3FXN1JWOFJxTkc0aWRPam0yMTZBSlRSRmo1X3luWEMzZjBaUjJDOFN6Tnk3M3htZFhPbF9XYWVYTThmMWdtYnplanYwR3EtdG4zd1R0RjBFMFRJTm1wbktjTTM4MmJBc1BSVElScGE2c1I3MXlvU0ZwVkxYOVZzV3FuejRQUFNhNjBXRHJ3RXNLdEF6aTR6ODNPNVg4VXdvWjBfN1d1VFpjZnVXNA?oc=5","date":"2026-03-03","type":"regulatory","source":"businesswire.com","summary":"Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - businesswire.com","headline":"Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5QVlc1aXhVQV9RdmFtRUQ5bzRLN1RMbGRGamRoLXdTUlRTdl85U2F0UlpTbXJIN3lIUURnMTEzVWs3U2ItR1RWZXQxbDdyYks1VlZiRlh6akhFTUJNZk11QzBpeGlxVHdjY3MzMmpxQTVhWkE2?oc=5","date":"2026-02-25","type":"regulatory","source":"statnews.com","summary":"A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA - statnews.com","headline":"A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQQmpCVklzZk5xWUFXcHNJYTJUN29aOVhuUUtreUlWSTVocm82VTdSNjJQdk5SaXlVWkdyT3NRckRucmVjT0p2WjE1UXNUR185NE93Ukh1Z3hBV2hxYUFCM19BSUxRTmVQR2htZDJEOFVwLUhDZ1U3UDlLb19zQU40RmxFV2xaQm1nZ0NoV3BWTGlJUmRMYmx5cm5XU3lYRHRaVDF5S2ZaSlpTREhiTmN2Qw?oc=5","date":"2026-01-12","type":"regulatory","source":"Fierce Pharma","summary":"Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma","headline":"Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNYWp5VDE5NTZzRmxwZ1ZYb3RwUXhaRVNnZV9vejRyUHhiRzFZaU8tX214NUtIQlo3TDFZd0VXUUJJcXgtbWJWQjJuVmFXd2FvX0IxNzI3YkpIZzhXTzA4MlF0Tkk0TDIyc1VNZ2hEcFRQYWhLdVFqQTdoZE84X3ZxSERsclFkbFhCSngtaVFZM0lob0hQSHJjYi12UXJHUGJFd0hRaUJJWm45M290WW9vT0R6ZzI1QTlUR1B1SE0xUlV2T255Mkt3?oc=5","date":"2026-01-12","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Atara's therapy for rare blood cancer - Reuters","headline":"US FDA declines to approve Atara's therapy for rare blood cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQdDdCelRHM1A3X0ZkZExVSlUzV1RFaVozM3NkQVRzN0xacGd0VXY2S2RCbUhJbE83SWxtOUh6c1N3bXFfRWZwZ1pWNElkdTRQbEl0bUR6eEc1YjA3dHprVkNFSGtidDRucmpuNTVzSkl4bWM2VUFBa3Nnd0Q4WVdOdENrbDlMd1VlMTJIMnpfQlAwN0xTZ2E4ZFNtZDRUMldzVU16NFBKMGJ6d0ltbjFmNnVsX2VJNGJXdlBNaVpocXpOUXNVT1o2UUFEYmthbXFOTHY4ekhTNnlMOEE?oc=5","date":"2026-01-12","type":"regulatory","source":"businesswire.com","summary":"Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - businesswire.com","headline":"Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE53MWRSYnBGa21SV2FVLWwxaU51cmlYRE13LWMtMnRiV01ocENmM2g2MXZ0SkMyWWRRQ21LZHFLaVJ2alVkY0dhQjR4VlVNNHU2YnBr?oc=5","date":"2026-01-12","type":"regulatory","source":"FirstWord Pharma","summary":"Atara, Pierre Fabre call out FDA U-Turn in second snub for Ebvallo - FirstWord Pharma","headline":"Atara, Pierre Fabre call out FDA U-Turn in second snub for Ebvallo","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-03","type":"deal","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymp","headline":"Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE84VFVIUXlNYkFUQ2k4cWUxcGRRZmhITWo2UFFoXzVhVzdCUW5TS0FKeFN5dGp5QWFRUVZMdEVhUk01VXlOX1oxcjN2ek1GejV0bWNZ?oc=5","date":"2025-09-04","type":"regulatory","source":"FirstWord Pharma","summary":"Friday Five – FDA continues CRL data dump, Sanofi spooks investors, Novartis doubles down on RNA…and more - FirstWord Pharma","headline":"Friday Five – FDA continues CRL data dump, Sanofi spooks investors, Novartis doubles down on RNA…and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxPSTRCTVl2bTlaOTJpc0MwQjVFODZxU2YtbmE2VXpQNHNtTDNfc1Qxa1lvZm5NTHNnYnFRcTg3ZVgwdWNGbVI3NVlYanhRRXJwOWZZTjFCTF9PclNuS3VYdU1zZzMzOHRhRTBoM0RFaWdOdHhHSXdRbnJKNGY3ZjVVdVlBUXJ5NThDd1dsR25YMExQZmFaYkozUnlBRVhoVFdwOXRJd0xYZjVFb2JSdE9kN1g2RmhaSms0Vzg1c0FQdTNRU21fYktNanhOZWxOdU9PQWdaMkdNZEZ3amxmMUlFc0VwNUVFRWtjMnh4Z3Y2NjVMVGlnaWVLbjQ4a29sM2V5SFVZemYya0V6SkhJaU91U1FxNURRSzJTbjhCWGQ1YUl4dw?oc=5","date":"2025-07-15","type":"pipeline","source":"PR Newswire","summary":"Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PR Newswire","headline":"Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Ata","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOQl9HOFVCa3FheV9BS2Q4ajM5VEhQbjJqdUdOdGhwYWdENlVaMnZkazc3UWQ2NEVQbXF4SjVxY1VncjR3OGs1TkJVN1Z4ZXZMQU11N3c3M2FKYmN1MExxb1R2cG9DaU9aSlhaaG9lQnpGTnJtb2JWUlpyYjVELWU4RUNHcjRDRDh5V0VKajJUb0E5M3ZwQmhtdDlZZjd1dDFYb0RrWG5CdDl3N29xamJjVHZaS3NxaUFRYW1sX3dPV2ZCY0FaQlhXcF9jdFJOWG8xenZHcVZSMXRyS2wxOV94YjduVE9WVnRfbnZN0gHwAUFVX3lxTE8temU4SFVFcFRSSDlIcS16WmQ1OHJHRjZMMngxeGNkUDdUR0JwRE9kNjdDTEJINWlfMURDVHJSalc0NHhDMHlTNUNSZmZmdUtGbElzZUFucTgxdF9zVkpBY2ViMHBJNkJpaHMtbjQzRzA0dkloWUJSRnJ2QlZzeFJxYzBYb3Qwamd5MGEyenZEVVFSaWJuMElFWGNwd3lzSmw3eGhNd1o4cF9udFBPcTJZVF80RGlUbGtLUnY4NXR4aS05TTRBTWVEdkd6TTFxRXc3TTBFV2hmNkhYOGtXRGlXa0k0Tnh6OGdPV1ZhdDdMRQ?oc=5","date":"2025-07-08","type":"earnings","source":"simplywall.st","summary":"We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st","headline":"We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQazZMOVZDbDA0STBLdUJHdkxNNmJOMmNJQWJzZFZSWEl4REdpbUsxMzh1bFpoMS1kZkVXQkJJdEctQ050eHlQMktLbGFmSmRtRGdmODg0Y09neTRRNklFV1JQeHV4eURxb1FTZDdXaG1PUW5sTFFmZVdZVzNEZFIxYVVtdFk0ZVd6ekNsZkpvYWVXcHJWMm9OQU9DSDBwN1U?oc=5","date":"2025-05-13","type":"regulatory","source":"Fierce Biotech","summary":"Atara lays off more staff this year despite FDA lifting clinical hold - Fierce Biotech","headline":"Atara lays off more staff this year despite FDA lifting clinical hold","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}